Aktis Oncology, Inc.

AKTS · United States

Share price · AKTS

$16.10-8.90 (-35.60%) 3M

close as of 2026-11-18 · 24h delayed · vol 435K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AKTS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+6.6%
  2. 2 Nov 2026-8.4%
  3. 6 Jul 2026-16.4%
  4. 16 Jun 2026+9.4%
  5. 12 Jun 2026+12.7%
  6. 12 May 2026+8.0%
  7. 9 Jan 2026+639900.0%

Share of unusual movement by asset

For each asset, the share of AKTS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
AKY-1189
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—100%
Sessions with no dated event—0%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
Nectin-4 (PVRL4)Radiopharmaceutical
Non-Small Cell Lung CancerBladder / Urothelial Cancer
Urothelial Carcinoma
Phase 1
B7-H3-targeted radioligand therapyRadiopharmaceutical
Metastatic Castration-Resistant Prostate Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.9M$32M$69M+ $425M short-term inv.$30M-$26M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.4M$25M$84M+ $435M short-term inv.$24M-$21M operating cash flowreport ↗
2026-Q1$3.2M$20M$373M+ $167M short-term inv.$18M-$24M operating cash flowreport ↗
2025-Q3$1.6M$16M$181M$16M-$15M operating cash flowreport ↗
2025-Q2$1.6M$19M$111M$18M-$16M operating cash flowreport ↗
2025-Q1$1.4M$16M$59M$15M-$17M operating cash flowreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$39M—report ↗

For the year ended December 31, 2025, Aktis Oncology reported collaboration revenue of $6.5M, up from $1.5M in 2024; R&D expenses of $67.5M, up from $41.0M; and a net loss of $63.7M, compared to $44.0M in 2024. Cash, cash equivalents and marketable securities totaled $226.8M at year-end, with a pro forma adjusted cash position of $562.1M after incorporating approximately $335.3M in net proceeds from the January 2026 IPO.

The FDA cleared IND applications for AKY-2519, a B7-H3-targeting miniprotein radioconjugate, allowing a Phase 1b trial expected to start in mid-2026, while the lead candidate AKY-1189 continues enrolling in a Phase 1b study and received Fast Track designation in February 2026, with preliminary Part 1 data expected in the first quarter of 2027. Management also guided that the pro forma adjusted cash position should fund operations into 2029, and it anticipates clinical imaging/dosimetry results for AKY-2519 in mid-2026, two early pipeline programs to reach development candidate nomination in Q1 2027, and an in-house GMP facility to be operational in the second half of 2026.

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$38M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($114.3M), 11 sales ($3.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Feldman Paul L · Chief Scientific OfficerOption exercise55,035$1.90$105KForm 4
2026-11-18Feldman Paul L · Chief Scientific OfficerOption exercise (derivative)55,035——Form 4
2026-09-23Czibere Akos · Chief Medical OfficerOption exercise12,500$4.95$62KForm 4
2026-09-23Czibere Akos · Chief Medical OfficerOpen-market sale5,099$20.19$103KForm 4
2026-09-23Czibere Akos · Chief Medical OfficerOpen-market sale7,401$21.03$156KForm 4
2026-09-23Czibere Akos · Chief Medical OfficerOption exercise (derivative)12,500——Form 4
2026-07-20Herrmann Ken · directorOption exercise3,506$0.08$280Form 4
2026-07-20Herrmann Ken · directorOption exercise1,350$1.91$3KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 35.2M shares ($563.9M).

#InstitutionSharesValue
1MPM BIOIMPACT LLC4,835,872$86.5M
2EcoR1 Capital, LLC4,824,469$86.3M
3Blue Owl Capital Holdings LP3,161,348$56.6M
4WELLINGTON MANAGEMENT GROUP LLP2,317,044$41.5M
5BlackRock, Inc.2,112,127$37.8M
6RTW INVESTMENTS, LP1,592,043$28.5M
7RA CAPITAL MANAGEMENT, L.P.1,503,084$26.9M
8JANUS HENDERSON GROUP PLC1,454,267$26.0M
9BAKER BROS. ADVISORS LP996,351$17.8M
10Octagon Capital Advisors LP960,847$17.2M
11Avidity Partners Management LP937,132$17.2M
12Merck & Co., Inc.952,844$17.0M
13VANGUARD CAPITAL MANAGEMENT LLC833,913$14.9M
14EVENTIDE ASSET MANAGEMENT, LLC507,000$9.1M
15GEODE CAPITAL MANAGEMENT, LLC491,936$8.8M